We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Technology 14.31%
3 Communication Services 13.23%
4 Financials 10.05%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
101
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.24M 0.06%
+1,000,000
New +$8.69M
ACIA
102
DELISTED
Acacia Communications Inc
ACIA
$7.3M 0.04%
100,000
+40,000
+67% +$2.77M
FPRX
103
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.8M 0.04%
+400,000
New +$5.01M
COGT icon
104
Cogent Biosciences
COGT
$6.37B
$6.74M 0.04%
+600,000
New +$6.59M
IMGN
105
DELISTED
Immunogen Inc
IMGN
$6.45M 0.04%
+1,000,000
New +$5.83M
MRVL icon
106
CALL
Marvell Technology
MRVL
$213B
$5.94M 0.04%
+125,000
New +$5.41M
CRIS icon
107
Curis
CRIS
$3.83M
$5.94M 0.04%
+1,813
New +$2.18M
STTK icon
108
Shattuck Labs
STTK
$756M
$5.24M 0.03%
+100,000
New +$3.21M
ISEE
109
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.21M 0.03%
754,740
– –
TGTX icon
110
TG Therapeutics
TGTX
$8.31B
$5.2M 0.03%
+100,000
New +$3.38M
ARWR icon
111
Arrowhead Research
ARWR
$12.3B
$5.19M 0.03%
67,600
-356,000
-84% -$22.8M
SVRA icon
112
Savara
SVRA
$1.15B
$5.12M 0.03%
4,452,086
– –
HMCOU
113
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
$4.41M 0.03%
+400,000
New +$4.44M
MASS icon
114
908 Devices
MASS
$441M
$4.27M 0.03%
+75,000
New +$4.38M
FDMT icon
115
4D Molecular Therapeutics
FDMT
$875M
$4.14M 0.02%
+100,000
New +$4.13M
KURA icon
116
Kura Oncology
KURA
$1.06B
$4.08M 0.02%
+125,000
New +$4.39M
EQ icon
117
Equillium
EQ
$146M
$3.75M 0.02%
700,000
– –
ALPN
118
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.52M 0.02%
200,000
-541,290
-73% -$5.31M
IVA
119
Inventiva
IVA
$1.11B
$2.32M 0.01%
160,000
-367,870
-70% -$4.77M
SPRY icon
120
ARS Pharmaceuticals
SPRY
$547M
$2.21M 0.01%
+47,620
New +$1.59M
BRMK.WS
121
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$1.94M 0.01%
7,174,613
– –
GOL
122
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
$843K 0.01%
85,838
– –
CEREW
123
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$758K ﹤0.01%
+134,175
New +$541K
ADAP
124
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,515,762
Closed -$20.1M
AMWL icon
125
American Well
AMWL
$202M
– –
-2,250
Closed -$1.33M
3 4
5
6 7

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2020 Portfolio in Review

As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
  • Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.